Joint Formulary & PAD

Formulary Search

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Search

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A-Z of Drugs

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Dementia (Galantamine - Dementia)

Records returned : 5 (on 16 Jul 2025 at 23:16:26). Return to search results for ' Dementia '.

Show Icon and Status Keys

Drug
Indication
Status
Restrictions/Comments
Formulary Status
Links
Indication :
Status :
See narrative
Formulations :
  • Not Specified
Restrictions / Comments:

Important

This entry has not yet been reviewed for inclusion on the joint formulary. However, this information has been published due to the ongoing requirement for prescribers to access the shared care agreement and other resources that were in place prior to the launch of the joint formulary.

Please refer to the list of agreed formulations and former traffic light status available on the PAD page (accessed by clicking the drug name).

 
Links :
Indication :
Status :
Blue
Formulations :
  • Capsules
  • Patches
Restrictions / Comments:

Important

Rivastigmine is BLUE (with information sheet) for those patients who are stable and suitable for discharge from specialist care.

This entry has not yet been reviewed for inclusion on the joint formulary. However, this information has been published due to the ongoing requirement for prescribers to access the shared care agreement and other resources that were in place prior to the launch of the joint formulary.

 
Links :
Indication :
Status :
Amber
Formulations :
  • Capsules
  • Patches
Restrictions / Comments:

Important

AMBER shared care applies for patients that are not suitable for discharge and who will continue to receive follow up by SABP.

This entry has not yet been reviewed for inclusion on the joint formulary. However, this information has been published due to the ongoing requirement for prescribers to access the shared care agreement and other resources that were in place prior to the launch of the joint formulary.

 
Links :
Indication :
Status :
See narrative
Formulations :
  • Not Specified
Restrictions / Comments:

Important

This entry has not yet been reviewed for inclusion on the joint formulary. However, this information has been published due to the ongoing requirement for prescribers to access the shared care agreement and other resources that were in place prior to the launch of the joint formulary.

Please refer to the list of agreed formulations and former traffic light status available on the PAD page (accessed by clicking the drug name).

 
Links :
Indication :
Status :
See narrative
Formulations :
  • Not Specified
Restrictions / Comments:

Important

This entry has not yet been reviewed for inclusion on the joint formulary. However, this information has been published due to the ongoing requirement for prescribers to access the shared care agreement and other resources that were in place prior to the launch of the joint formulary.

Please refer to the list of agreed formulations and former traffic light status available on the PAD page (accessed by clicking the drug name).

 
Links :